{
    "clinical_study": {
        "@rank": "35026", 
        "arm_group": [
            {
                "arm_group_label": "Placebo Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dose A - sodium acetate buffer (0 mg rhPDGF-BB)"
            }, 
            {
                "arm_group_label": "0.45 mg rhPDGF-BB", 
                "arm_group_type": "Experimental", 
                "description": "Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB"
            }, 
            {
                "arm_group_label": "0.75 mg rhPDGF-BB", 
                "arm_group_type": "Experimental", 
                "description": "Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB"
            }, 
            {
                "arm_group_label": "1.5 mg rhPDGF-BB", 
                "arm_group_type": "Experimental", 
                "description": "Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB"
            }, 
            {
                "arm_group_label": "3.0 mg rhPDGF-BB", 
                "arm_group_type": "Experimental", 
                "description": "Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether recombinant human platelet-derived growth\n      factor (rhPDGF-BB) Injection is effective in the treatment of lateral epicondylitis (tennis\n      elbow)."
        }, 
        "brief_title": "Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Lateral Epicondylitis", 
        "condition_browse": {
            "mesh_term": "Tennis Elbow"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject has signed the Institutional Review Board (IRB) approved Informed Consent\n             Form specific to this study prior to enrollment\n\n          2. Subject has a clinical diagnosis of lateral epicondylitis\n\n          3. Subject's symptoms can be reproduced with resisted supination or wrist dorsiflexion\n\n          4. Subject's symptoms have persisted for at least 3 months despite conservative\n             treatment that includes one or combinations of:\n\n               1. Physical therapy\n\n               2. Splinting\n\n               3. Nonsteroidal antiinflammatory drug (NSAID)\n\n               4. Corticosteroid injection\n\n          5. Subject is independent, ambulatory, and can comply with all post-injection\n             evaluations and visits\n\n          6. Subject is 21-80 years of age and considered to be skeletally mature\n\n        Exclusion Criteria:\n\n          1. Subject has undergone previous corticosteroid injection therapy to the effected elbow\n             in less than three months prior to enrollment\n\n          2. Subject has received previous Platelet Rich Plasma (PRP) injection to the affected\n             elbow\n\n          3. Subject is deemed to require a corticosteroid injection into the affected elbow\n             during the course of the study\n\n          4. Subject uses chronic medications known to affect the skeleton (e.g. glucocorticoid\n             usage >10mg/day)\n\n          5. Subject has undergone surgical intervention to the affected elbow for the treatment\n             of lateral epicondylitis\n\n          6. Subject has a positive medical history of any of the following:\n\n               1. medial epicondylitis\n\n               2. radial tunnel syndrome\n\n               3. carpal tunnel syndrome\n\n               4. septic or gouty arthritis\n\n               5. cervical radiculopathy\n\n               6. trauma to the affected elbow within the past 6 weeks\n\n               7. neuromuscular or musculoskeletal deficiency, which limits the ability to perform\n                  functional measurement (e.g. grip strength test)\n\n          7. Subject currently has an acute infection at the injection site\n\n          8. Subject has tested positive or been treated for a malignancy in the past or is\n             suspected of having a malignancy or are currently undergoing radio- or chemotherapy\n             treatment for a malignancy anywhere in the body, whether adjacent to or distant from\n             the proposed rhPDGF-BB Injection treatment site\n\n          9. Subject is physically or mentally compromised (e.g. currently being treated for a\n             psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that\n             the Investigator judges the subject to be unable or unlikely to remain compliant\n\n         10. Subject has an allergy to yeast-derived products\n\n         11. Subject has received an investigational therapy or approved therapy for\n             investigational use within 30 days of injection procedure or during the follow-up\n             phase of this study\n\n         12. Subject is a prisoner, or is known or suspected to be transient\n\n         13. Subject's condition represents a worker's compensation case\n\n         14. Subject is currently involved in a health-related litigation procedure\n\n         15. Subject has documented evidence of a history (e.g. liver testing) of drug/alcohol\n             abuse within the 12 months prior to screening for study entry\n\n         16. Subject is pregnant, or able to become pregnant but not practicing a\n             medically-accepted form of birth control, and/or intending to become pregnant during\n             this study period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746420", 
            "org_study_id": "BMTI-2010-02"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo Control", 
                "0.45 mg rhPDGF-BB", 
                "0.75 mg rhPDGF-BB", 
                "1.5 mg rhPDGF-BB", 
                "3.0 mg rhPDGF-BB"
            ], 
            "description": "Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection", 
            "intervention_name": "rhPDGF-BB Injection", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Platelet-derived growth factor BB"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "elbow", 
        "lastchanged_date": "December 10, 2012", 
        "location": [
            {
                "contact": {
                    "email": "mhill@azresearchcenter.com", 
                    "last_name": "Maria Hill", 
                    "phone": "602-773-3019"
                }, 
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85023"
                    }, 
                    "name": "Arizona Research Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Joseph Gimbel, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Louise Taber, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jcandito@tucsonortho.com", 
                    "last_name": "Jelena Candito", 
                    "phone": "520-784-6466"
                }, 
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85712"
                    }, 
                    "name": "Tucson Orthopaedic Institute"
                }, 
                "investigator": [
                    {
                        "last_name": "Nebojsa Skrepnik, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Brian Nielsen, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Joel Goode, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Andrew Mahoney, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase II Randomized, Single Ascending Dose, Double-blinded, Placebo Controlled, Multi-center Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis", 
        "overall_official": {
            "affiliation": "Brown University", 
            "last_name": "Edward Akelman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Elbow pain as measured by the Visual Analogue Scale", 
                "measure": "Elbow pain", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Disability and symptoms measured by the Disabilities of the Arm, Shoulder, and Hand (DASH) Score", 
                "measure": "Disability and symptoms", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Pain and disability measured by the Patient Rated Tennis Elbow Evaluation (PRTEE)", 
                "measure": "Pain and disability", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Sincerity of effort measured by Grip Strength testing", 
                "measure": "Sincerity of effort", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746420"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse event reporting (e.g. incidence, relationship with treatment, severity)", 
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "source": "BioMimetic Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioMimetic Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}